Date and Location | Monday, 11 October 2010
20.00 – 22.00
The Melia Milano Hotel
Via Masaccio 19
20149 Milan, Italy
|
Faculty | Chairman:
Stanley Kaye, MD, FRCP
The Royal Marsden Hospital & Institute of Cancer Research
Sutton, United Kingdom
Faculty:
Robert A. Burger, MD, FACOG, FACS
Fox Chase Cancer Center
Philadelphia, Pennsylvania, USA
Nicoletta Colombo, MD
University of Milan-Bicocca
Milan, Italy
Andres Poveda, MD
Fundacion Instituto Valenciano
de Oncologia
Valencia, Spain
|
Target Audience | This educational activity is designed for gynecologic oncologists, medical oncologists, and other healthcare professionals involved and/or interested in the management of patients with ovarian cancer. |
|
|
Meeting Overview |
On behalf of Stanley Kaye, MD, FRCP, symposium chairman, we are pleased to invite you to our symposium “Evolving Strategies in the Management of Advanced Ovarian Cancer” a prIME Oncology event on 11 October during the 2010 ESMO Congress.
During this educational seminar, leaders in the field will discuss targeted approaches to therapy in this rapidly advancing area and clinical issues encountered daily by practicing oncologists.
|
Agenda |
| |
Reception |
| 20.00 |
Welcome and introduction
Stanley Kaye, MD, FRCP
|
20.10
|
Defining the rationale and role for targeted therapy in ovarian cancer
Nicoletta Colombo, MD
|
20.30
|
Panel commentary |
| 20.35 |
Targeting angiogenesis: Where are we in 2010?
Robert A. Burger, MD, FACOG, FACS |
20.55
|
Panel commentary |
21.00
|
Beyond antiangiogenesis: What are the options?
Andres Poveda, MD
|
21.20
|
Panel commentary |
| 21.25 |
Challenging the experts: Hot topics in the modern management of ovarian cancer
All Faculty |
| 21.55 |
Summary and conclusion
Stanley Kaye, MD, FRCP
|
|
|
Learning Objectives | After successful completion of this educational activity, participants should be able to:
- Discuss currently available management strategies for patients with ovarian cancer and the unmet need for new therapeutic options within this patient population
- Define the rationale for various molecular targets as they apply to the management of advance ovarian cancer
- Evaluate data from recent clinical trials involving the use of targeted therapies in the management of patients with epithelial ovarian cancer
|
|
|
|
Support |
Financial support for this activity
has been provided by
F. Hoffmann-La Roche Ltd.
|
|
